Last reviewed · How we verify

NCT03632330

Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysis

Completed Last updated 6 April 2023
What this trial tests

trial testing Dexmedetomidine in Gastrointestinal Endoscopy in 6,963 participants. Completed in 7 March 2018.

Timeline
5 February 2018
Primary endpoint
7 March 2018
7 March 2018

Quick facts

Lead sponsorPfizer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment6,963
Start date5 February 2018
Primary completion7 March 2018
Estimated completion7 March 2018
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Pfizer — full company profile →

Who can join

12 and older, any sex, with Gastrointestinal Endoscopy or Sedation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to compare the efficacy and safety of dexmedetomidine with other sedatives in sedation during endoscopy by analyzing the most recently published interventional trials and observational studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Gastrointestinal Endoscopy

Currently open trials in the same condition.

Other Pfizer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing